The Cigna Group (CI) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 282.38B USD | |
| Stock-based compensation | (m) | |
| Operating income | 9.96B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $282.38B | (m) | $9.96B | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $277.89B | (m) | $9.59B | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $274.90B | (m) | $9.20B | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $268.08B | (m) | $9.03B | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $262.02B | (m) | $9.03B | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $255.37B | (m) | $9.13B | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $247.12B | (m) | $9.42B | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $232.59B | (m) | $9.30B | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $217.94B | (m) | $8.97B | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $206.00B | (m) | $8.78B | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $195.26B | (m) | $8.54B | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $189.90B | (m) | $8.19B | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $186.13B | (m) | $8.09B | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $183.03B | (m) | $8.24B | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $180.52B | (m) | $8.41B | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $180.45B | (m) | $8.23B | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $179.46B | (m) | $8.38B | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $177.11B | (m) | $8.14B | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $174.08B | (m) | $7.93B | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $170.10B | (m) | $7.74B | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $166.77B | (m) | $7.56B | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $162.90B | (m) | $8.05B | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $160.40B | (m) | $8.15B | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $156.93B | (m) | $8.37B | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $154.53B | (m) | $8.38B | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $154.09B | (m) | $7.91B | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $153.57B | (m) | $8.08B | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $129.62B | (m) | $7.08B | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $102.52B | (m) | $6.08B | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $75.18B | (m) | $5.08B | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $48.65B | (m) | $4.16B | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $44.98B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $43.90B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $42.79B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $41.81B | (m) | $3.94B | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $39.84B | (m) | $3.09B | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health, Inc. (ELV) | United States | $86.364B | 16.90 |
| HUMANA INC (HUM) | United States | $45.651B | 18.44 |
| CENTENE CORP (CNC) | United States | $30.588B | -6.22 |
| MOLINA HEALTHCARE, INC. (MOH) | United States | $10.091B | -1,697.50 |
| Alignment Healthcare, Inc. (ALHC) | United States | $1.593B | 121.28 |
| TRUPANION, INC. (TRUP) | United States | $0.984B | |
| UNITEDHEALTH GROUP INC (UNH) | United States | $336.652B | 26.62 |